# DEA Synthetic Cannabinoids Schedule I Placement 2026 Updates > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-2026/ > **Published:** 2026-06-17T17:27:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:24:12-04:00 > **Clinical Summary:** Explore the DEA synthetic cannabinoids Schedule I placement 2026 updates impacting clinical practice and federal regulatory policy on cannabinoid substances. --- Policy WatchJune 17, 2026. 5 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal Register [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products. [Read more →](https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) Score 70Federal Register [Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements](https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products) The DEA proposes rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III, potentially easing access for clinicians and patients while maintaining federal control. [Read more →](https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products) Score 70Federal Register [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products. [Read more →](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) Score 70Federal Register [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis. [Read more →](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) Score 70Federal Register [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in illicit cannabis products, into Schedule I, impacting prescribing, dispensing, and research involving the substance. [Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) Digest-Level Clinical Commentary Dr. Caplan’s Take These regulatory actions reflect a bifurcated federal approach where synthetic cannabinoids and novel psychoactive substances face increasingly aggressive scheduling while FDA-approved cannabis-derived medications move toward rescheduling, creating a clarifying but paradoxical landscape for clinical practice. The rescheduling of marijuana-derived pharmaceuticals to Schedule III acknowledges medical utility that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioners have long observed clinically, yet the concurrent scheduling of novel synthetics suggests regulatory focus on abuse potential rather than therapeutic applications. For my practice, this signals that [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) medicine will likely receive greater legitimacy through traditional pharmaceutical pathways, while whole-plant cannabis remains in a regulatory gray zone that complicates research, standardization, and consistent [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/). Clinical Perspective These regulatory actions reflect ongoing efforts to control the proliferation of synthetic cannabinoids and novel psychoactive substances that circumvent existing [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) laws. The inclusion of multiple synthetic cannabinoid analogs alongside traditional enforcement actions demonstrates a consistent pattern of reactive scheduling to address compounds developed specifically to evade legal restrictions. The concurrent rescheduling of FDA-approved cannabis products to Schedule III represents a significant shift in federal drug policy that may have implications for clinical access and research opportunities for these medications. [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/)[Drug Scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/)Regulatory ChangesSynthetic CannabinoidsFederal Policy 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+June+17%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+June+17%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 2-Fluorodeschloroketamine in Schedule I - Schedules of Controlled Substances: Placement of Diphenidine in Schedule I [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Policy Watch: 19 Regulatory Updates — June 16, 2026 Review the latest regulatory developments leading up to June 17, 2026, including synthetic cannabinoid scheduling and federal policy shifts. Read More [Policy Watch: 6 Regulatory Updates — June 18, 2026](https://cedclinic.com/dea-scheduling-synthetic-drugs-june-18-2026/) Explore subsequent regulatory updates following the June 17 announcements, focusing on [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) and cannabinoid regulations. [Explore Updates](https://cedclinic.com/dea-scheduling-synthetic-drugs-june-18-2026/) [Policy Watch: 20 Regulatory Updates — June 22, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-placement-june-2026/) Stay informed on the continuing federal regulatory landscape affecting cannabinoids and synthetic substances in late June 2026. [Stay Informed](https://cedclinic.com/dea-synthetic-opioids-schedule-i-placement-june-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).